As Washington prepares for what could become the most significant federal cannabis reform in half a century, InterCure (NASDAQ:INCR) is quietly positioning itself ahead of the curve. A leading GMP-certified medical cannabis producer, the company is reinforcing its scientific foundation just as U.S. policy momentum accelerates.
When former President Donald Trump confirmed that his administration was “looking at reclassification” and would make “a determination over the next few weeks,” it sparked the most serious federal conversation around cannabis reform in decades. Moving cannabis from Schedule I to Schedule III under the Controlled Substances Act would mark the first formal acknowledgment of its medical use — a change that could expand banking access, reduce tax burdens, and attract long-term institutional capital into a market that has long been constrained.
For global operators built to pharmaceutical standards, such a shift could be transformative.
Building on Momentum: From ISHI to Cannasoul
Just weeks after announcing the acquisition of ISHI, a U.S. cannabis technology firm with partnerships at established American cultivation facilities, InterCure took another major strategic step.
The company entered a definitive agreement with Cannasoul R&D Ltd., a recognized global leader in cannabinoid research founded by Professor Dedi Meiri of the Technion – Israel Institute of Technology. Under the agreement, InterCure will acquire a 28% stake in Cannasoul, with the right to increase its holding to 51% within two years, building one of the industry’s most advanced science-driven ecosystems.
Cannasoul’s proprietary analytics and biological validation platforms enable detailed mapping of cannabinoid compounds and mechanisms of action. Combined with InterCure’s GMP-grade production and commercial reach, the partnership creates a strong bridge between academic research and real-world medical products.
Professor Meiri — one of the field’s most cited researchers – will also chair InterCure’s new Scientific Advisory Board, aligning state-of-the-art research with the company’s product and regulatory roadmap.
Science Meets Policy
This scientific expansion comes as U.S. policy appears to be moving toward more evidence-based cannabis regulation. Should rescheduling proceed, cannabis companies with validated research, pharmaceutical-grade production, and GMP certification could gain first-mover advantages in an evolving federal market.
InterCure’s combination of Israeli R&D leadership and global commercialization capabilities positions it well for that landscape. The company’s operations span multiple international markets, supported by a vertically integrated supply chain that meets strict pharmaceutical manufacturing standards.
Financial Strength and Strategic Discipline
InterCure stands out in the global cannabis industry for its operational scale and consistent positive adjusted EBITDA. According to company filings, 2024 revenue reached approximately NIS 239 million (≈US $64 million), with adjusted EBITDA of NIS 24 million. In the first half of 2025, InterCure reported NIS 130 million in revenue and NIS 12 million in operating cash flow, reflecting continued stability even amid market and geopolitical challenges — including the temporary disruption following the October 7 attacks in Israel.
The company ended 2024 with a strong cash position of roughly US $80 million, one of the healthiest balance sheets among global cannabis operators. Its ongoing acquisitions and scientific partnerships are being executed with clear fiscal discipline.
A Defining Moment for the Cannabis Sector
If the Trump administration finalizes cannabis reclassification, it would represent the most consequential policy shift in 50 years — potentially normalizing taxation and banking, attracting institutional investment, and redefining competition across the sector.
Major public operators such as Tilray (NASDAQ: TLRY), Canopy Growth (NASDAQ: CGC), and Curaleaf (OTC: CURLF) have already seen renewed investor interest. Yet many North American producers still face fragmented, state-based frameworks. By contrast, InterCure’s pharmaceutical-grade model and global experience could allow it to move quickly as the U.S. environment evolves.
Its research-driven strategy, now bolstered by the Cannasoul alliance, underscores its focus on combining scientific credibility, compliance, and scalability – the very attributes that could define leadership in a newly regulated U.S. market.
The Bottom Line
If the U.S. cannabis rescheduling process advances, the companies best positioned to benefit will be those that combine science, compliance, and financial strength.
InterCure has spent years building exactly that – from its GMP-certified infrastructure and profitable operations to its expanding R&D ecosystem with Cannasoul and its strategic entry point into the U.S. through ISHI.
As the rescheduling review approaches a critical phase, InterCure emerges as one of the few global cannabis operators aligning robust science with fiscal discipline — poised to benefit from a once-in-a-generation regulatory shift.
Subscribe for Similar Reports
Read more from The Finance Herald
- The Next Big Biotech Breakout Could Come From Phage Therapy – These Micro Caps Are Leading It
- Why Your Vibe-Coded App Is Probably a Security Nightmare (And What to Do About It)
- With America’s Power Grid on the Brink, Is This Microcap Drone Stock the Wild Card?
- The Questions Every CRO Should Ask Before Renewing Salesforce CPQ
- Could This Micro-Cap MedTech Be the Next Big Story in Respiratory Care?
Disclaimer & Disclosure: This content is a form of paid promotional content and advertising. Wall Street Wire receives cash compensation from InterCure Ltd for promotional media services provided on an ongoing subscription basis. This content is for informational purposes only and does not constitute financial advice. Wall Street Wire is not a broker-dealer or investment adviser. Full compensation details and information regarding the operator of Wall Street Wire alongside the full disclaimers and disclosures this content is subject to are available wallstwire.ai/disclosures. We are not responsible estimates market size figures that may be cited in this article nor do we endorse them, they are quoted based on publicly available news reports and additional price targets or figures may exist that may not have been quoted. Readers are advised to refer to the full reports mentioned on various systems and the disclaimers/disclosures they may be subject to. This article was not reviewed or approved by the issuer prior to publication and should not be considered an official communication by it.